AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

AbbVie (ABBV) stock in focus after a Phase 3 trial setback for leukemia therapy venetoclax marketed with Roche (RHHBY) in ...

The VERONA trial evaluated the safety and efficacy of venetoclax with azacitidine in treatment-naïve adults with higher-risk MDS.

AbbVie (ABBV) announced the global Phase 3 Vevrona trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome did not meet the ...

A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings ...

Personalized drug treatments have outperformed chemotherapy for leukemia patients in a trial led by Leeds researchers. Newly ...

The AbbVie-Roche cancer drug venetoclax failed to meet its primary endpoint in a phase 3 trial to treat newly diagnosed ...

AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival. The drugmaker ...

AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) ...

Combination therapies for chronic lymphocytic leukemia (CLL) offer improved depth of response and potentially longer survival ...

The Flair trial saw two targeted cancer drugs perform better than standard chemotherapy, halting disease progression in 94% ...